跳至主要内容
临床试验/NCT04026334
NCT04026334终止不适用

Evaluation of Hydromechanical Cleansing Using Normal Saline With V.A.C. VERAFLO CLEANSE CHOICE™ Dressing and NPWT-d to Promote Increased Healthy Wound Bed Tissue

3M2 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2019年7月25日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
3M
入组人数
8
试验地点
2
主要终点
Percent change in wound bed surface area (cm2) of clean, healthy, viable tissue

研究概览

简要总结

The study goal is to evaluate the ability of the V.A.C. ULTA™ Negative Pressure Wound Therapy System and V.A.C. VERAFLO CLEANSE CHOICE ™ (VFCC) dressing system with saline as an irrigant in increasing viable tissue in full thickness wounds (such as chronic, acute, traumatic, sub-acute, and dehisced wounds and/or ulcers) with difficult to manage bioburden and slough.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • is anticipated to be hospitalized for the duration of treatment.
  • is ≥22 years of age or their legally authorized representative is able to provide informed consent.
  • has a full thickness wound (such as chronic, acute, traumatic, sub-acute, and dehisced wounds and/or ulcers) measuring ≥4cm in length and ≥4cm in width (before removal of eschar at the bedside) excluding undermining/tunneling.
  • has, in the opinion of the investigator, no more than 2/3 of the visible wound bed surface area considered to be clean, healthy, and viable. If eschar is present at baseline, it must be removed by bedside debridement prior to assessing the percentage of clean, healthy, and viable wound bed.
  • has a negative urine or serum pregnancy test at screening (if female and has potential for pregnancy) and is willing to take precautionary measures to prevent pregnancy during the duration of the study (up to 9 days).

排除标准

  • has been diagnosed with malignancy in the wound.
  • has untreated osteomyelitis.
  • has an untreated systemic infection.
  • has active cellulitis in the peri wound area.
  • has a known allergy or hypersensitivity to study materials: dressing and/or dressing components such as acrylic adhesives or polyurethane.
  • has, in the opinion of the investigator, a clinically significant condition that would impair the Subject's ability to comply with the study procedures.
  • has had radiation directly to the wound.
  • has been diagnosed with a major vascular deficit limiting arterial inflow to the wound region, as determined by the Investigator's interpretation of the Subject's medical history.
  • has eschar in the wound that cannot be removed by beside or sharp and/or mechanical debridement.
  • is participating in another interventional clinical trial for the duration of the study.
  • has unexplored fistulas in the wound or fistulas in the wound that connect to other body cavities.
  • has inadequate hemostasis at the wound site, as determined by the investigator.

结局指标

主要结局

Percent change in wound bed surface area (cm2) of clean, healthy, viable tissue

时间窗: Baseline to Day 6-9

次要结局

  • Percent change in total wound area (cm2)(Baseline to Day 6-9)
  • Percent change in total wound volume (cm3)(Baseline to Day 6-9)
  • Physician assessment of the need for surgical debridement(Day 6-9)

研究者

发起方
3M
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Evaluation of V.A.C. VERAFLO CLEANSE CHOICE™... | 临床试验